Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection.

Salpini R, Battisti A, Colagrossi L, Di Carlo D, Fabeni L, Piermatteo L, Cerva C, Lichtner M, Mastroianni C, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Angelico M, Sarmati L, Andreoni M, Perno CF, Ceccherini-Silberstein F, Svicher V.

J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13101. [Epub ahead of print]

PMID:
30974483
2.

Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment.

Pisaturo M, Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Claar E, Precone D, Stornaiuolo G, Stanzione M, Gentile I, Brancaccio G, Martini S, Masiello A, Megna AS, Coppola C, Federico A, Sagnelli E, Persico M, Lanza AG, Marrone A, Gaeta GB, Coppola N.

Antivir Ther. 2019 Feb 13. doi: 10.3851/IMP3296. [Epub ahead of print]

PMID:
30758299
3.

Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir.

Viganò M, Loglio A, Labanca S, Zaltron S, Castelli F, Andreone P, Messina V, Ganga R, Coppola N, Marrone A, Russello M, Marzano A, Tucci A, Taliani G, Fasano M, Fagiuoli S, Villa E, Bronte F, Santantonio T, Brancaccio G, Occhipinti V, Facchetti F, Grossi G, Rumi M, Lampertico P.

Liver Int. 2019 Mar;39(3):484-493. doi: 10.1111/liv.14017. Epub 2019 Jan 7.

PMID:
30525275
4.

Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes.

Sasso FC, Rinaldi L, Lascar N, Marrone A, Pafundi PC, Adinolfi LE, Marfella R.

J Diabetes Res. 2018 Oct 4;2018:3106056. doi: 10.1155/2018/3106056. eCollection 2018. Review.

5.

Endotoxinemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress.

Zampino R, Marrone A, Rinaldi L, Guerrera B, Nevola R, Boemio A, Iuliano N, Giordano M, Passariello N, Sasso FC, Albano E, Adinolfi LE.

Infection. 2018 Dec;46(6):793-799. doi: 10.1007/s15010-018-1185-6. Epub 2018 Jul 31.

PMID:
30066228
6.

The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C.

Adinolfi LE, Rinaldi L, Marrone A, Giordano M.

Expert Rev Anti Infect Ther. 2018 Aug;16(8):595-597. doi: 10.1080/14787210.2018.1505500. Epub 2018 Aug 1. No abstract available.

PMID:
30047799
7.

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group.

Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28.

PMID:
29808463
8.

Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease.

Adinolfi LE, Marrone A, Rinaldi L.

Hepatobiliary Surg Nutr. 2018 Apr;7(2):143-146. doi: 10.21037/hbsn.2018.02.01. No abstract available.

9.

Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.

Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A.

J Hepatol. 2018 Jul;69(1):18-24. doi: 10.1016/j.jhep.2018.02.015. Epub 2018 Mar 2.

PMID:
29505844
10.

Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis.

Rinaldi L, Ascione A, Messina V, Rosato V, Valente G, Sangiovanni V, Zampino R, Marrone A, Fontanella L, de Rosa N, Orabona P, Buonomo C, Chirianni A, Adinolfi LE, Piai G.

Infection. 2018 Apr;46(2):231-238. doi: 10.1007/s15010-017-1113-1. Epub 2018 Jan 15.

PMID:
29335905
11.

Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.

Adinolfi LE, Nevola R, Guerrera B, D'Alterio G, Marrone A, Giordano M, Rinaldi L.

J Gastroenterol Hepatol. 2018 Jul;33(7):1379-1382. doi: 10.1111/jgh.14067. Epub 2018 Feb 27.

PMID:
29228501
12.

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.

Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Erratum in: Lancet Gastroenterol Hepatol. 2017 Jun;2(6):e3.

PMID:
28497758
13.

Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study.

Ruggiero G, Marrone A, Rainone I, Boemio A, Adinolfi LE, Pasquale G, Rinaldi L, Guerrera B, Andreana L, Zampino R; Thecla Study Group.

Infez Med. 2016 Dec 1;24(4):278-286.

14.

CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection.

Coppola N, Zampino R, Bellini G, Stanzione M, Capoluongo N, Marrone A, Macera M, Adinolfi LE, Giudice EM, Gentile I, Sagnelli E, Rossi F.

Dig Liver Dis. 2016 Nov;48(11):1364-1369. doi: 10.1016/j.dld.2016.07.005. Epub 2016 Jul 15.

PMID:
27476469
15.

Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.

Cleo Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D'Adamo G, D'Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A.

World J Hepatol. 2016 Aug 8;8(22):949-56. doi: 10.4254/wjh.v8.i22.949.

16.

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations.

Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R.

Int J Mol Sci. 2016 May 25;17(6). pii: E803. doi: 10.3390/ijms17060803. Review.

17.

Risk factors for carotid atherosclerosis in chronic hepatitis C: no role of the APOC3 variant.

Zampino R, Florio A, Grandone A, Capoluongo N, Marrone A, Minichini C, Adinolfi LE, Miraglia del Giudice E, Coppola N.

Infez Med. 2015 Sep;23(3):285-7. No abstract available.

18.

Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment.

Zampino R, Alessio L, Marrone A, Stanzione M, Boemio A, Grandone A, Minichini C, Pisaturo M, Starace M, Adinolfi LE, Sagnelli E, Coppola N.

Infez Med. 2015 Jun;23(2):134-9.

19.

Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B.

Zampino R, Coppola N, Cirillo G, Boemio A, Grandone A, Stanzione M, Capoluongo N, Marrone A, Macera M, Sagnelli E, Adinolfi LE, del Giudice EM.

Dig Dis Sci. 2015 Oct;60(10):3005-10. doi: 10.1007/s10620-015-3716-7. Epub 2015 May 19.

PMID:
25986529
20.

Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview.

Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, Zampino R, Rinaldi L, Sellitto A, Giordano M, Marrone A.

World J Gastroenterol. 2015 Feb 28;21(8):2269-80. doi: 10.3748/wjg.v21.i8.2269. Review.

Supplemental Content

Loading ...
Support Center